Mulai
NOVARTIS N

Novartis AG (NOVN)

Oleh mgiuliani
The Swiss-based drugmaker missed consensus expectations on both earnings and sales in the first quarter, the results were hurt by a historically weak cough and cold season. Novartis’ cornerstone innovative medicines division turned in with sales +4%. Stock is currently pegged to underperform the broader market and our 18-month projections reflect below-average upside potential. But as said in the chart, a "buy and hold" strategy give a 3.50% dividend yield in CHF.
Trend Analysis
mgiuliani
Juga di:

Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.